Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio

Patent ExpiryresmetiromPositive

AI Analysis

Summary

Madrigal Pharmaceuticals announced that the USPTO issued three new patents for resmetirom, strengthening the company's intellectual property portfolio for its MASH therapeutic.

Outcome Details

Three new resmetirom patents issued by USPTO

Importance:4/10

Sentiment:

0.60

patentintellectual propertyresmetiromMASHUSPTO

Related Companies

$MDGL

Read the original article

Published by GlobeNewswire Pharma on July 13, 2026 12:00 PM

Read Original